Advanced Renal Cell Carcinoma

Oncology·MeSH: Carcinoma, Renal Cell

Prevalence

48.0 / 100K

Incidence

15.0 / 100K/yr

12 drugs in development·8 companies·8 clinical trials

Drug Pipeline by Phase

Approved(3)

Phase 3(4)

Drug	Company
Balstilimab	ENANTA PHARMACEUTICALS INC (ENTA)
Cabozantinib	BRISTOL MYERS SQUIBB CO (BMY)
Cabozantinib S-malate	Royalty Pharma plc (RPRX)
Pumitamig	BRISTOL MYERS SQUIBB CO (BMY)

Phase 2(3)

Drug	Company
ABT-869	AbbVie Inc. (ABBV)
balstililmab	AGENUS INC (AGEN)
Botensilimab	ENANTA PHARMACEUTICALS INC (ENTA)

Phase 1(2)

Drug	Company
Balstilimab	AGENUS INC (AGEN)
Botensilimab	AGENUS INC (AGEN)

BioSniper tracks 12 drugs in development for Advanced Renal Cell Carcinoma across 8 companies.

There are 8 clinical trials targeting Advanced Renal Cell Carcinoma tracked by BioSniper.

The estimated prevalence of Advanced Renal Cell Carcinoma is approximately 48.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.